Biocartis, Pronota diagnostic news

Biocartis spun out newco MyCartis (Lausanne, Switzerland), a combination of Pronota and Biocartis' Evalution unit, which was developing Biocartis' Evalution multiplex assay technology for protein and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota discovers and validates biomarker panels. Biocartis is majority owner of the newco, which raised EUR15 million ($19.7 million) from RMM; Valiance; and Biover II. Paul Ladestein, who was business manager for Biocartis' Evalution business unit, is MyCartis' CEO. ...